Bank of America Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its target price reduced by equities research analysts at Bank of America from $145.00 to $139.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price points to a potential upside of 61.89% from the company’s current price.

Other analysts have also issued research reports about the company. HC Wainwright decreased their price target on Rhythm Pharmaceuticals from $125.00 to $110.00 and set a “buy” rating on the stock in a report on Monday, March 2nd. Morgan Stanley cut their price objective on shares of Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating on the stock in a research report on Tuesday. Wells Fargo & Company increased their target price on shares of Rhythm Pharmaceuticals from $136.00 to $143.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Zacks Research upgraded shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. Finally, Guggenheim raised their target price on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Rhythm Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $131.13.

Rhythm Pharmaceuticals Price Performance

Shares of NASDAQ RYTM opened at $85.86 on Tuesday. Rhythm Pharmaceuticals has a 1-year low of $45.90 and a 1-year high of $122.20. The business’s 50 day moving average is $99.45 and its two-hundred day moving average is $102.69. The stock has a market capitalization of $5.86 billion, a P/E ratio of -27.61 and a beta of 2.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.06. The business had revenue of $57.25 million during the quarter, compared to analyst estimates of $56.16 million. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The company’s revenue for the quarter was up 36.9% on a year-over-year basis. During the same period last year, the company earned ($0.72) EPS. As a group, equities research analysts anticipate that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 5,614 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the transaction, the chief accounting officer owned 160 shares of the company’s stock, valued at $14,329.60. This represents a 97.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Hunter C. Smith sold 4,385 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the sale, the chief financial officer owned 110,512 shares in the company, valued at approximately $11,190,445.12. The trade was a 3.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 27,267 shares of company stock valued at $2,719,955. 6.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in RYTM. EverSource Wealth Advisors LLC lifted its holdings in Rhythm Pharmaceuticals by 303.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after buying an additional 200 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after acquiring an additional 141 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Rhythm Pharmaceuticals by 1,110.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after acquiring an additional 322 shares in the last quarter. Optiver Holding B.V. increased its position in shares of Rhythm Pharmaceuticals by 65.2% during the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after acquiring an additional 144 shares during the period. Finally, SBI Securities Co. Ltd. increased its position in shares of Rhythm Pharmaceuticals by 73.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after acquiring an additional 145 shares during the period.

Key Headlines Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Several major Wall Street firms lowered price targets but retained buy/overweight ratings, leaving substantial upside in consensus targets (new PTs reported in roughly the $100–$152 range). That continued analyst support may limit longer-term downdraft if management provides mitigating data or subgroup benefit. Analyst Reactions
• Positive Sentiment: A recent valuation piece argues that the stock’s pullback has improved entry valuation relative to its long-term return profile, suggesting some investors may view the decline as a buying opportunity if they believe in Rhythm’s broader franchise and pipeline. A Look At Rhythm Pharmaceuticals Valuation
• Neutral Sentiment: Rhythm released a transcript/slideshow discussing topline results and management insights from the Phase 3 EMANATE program; this provides more context but investors will need the full dataset and company guidance to reassess commercial and regulatory prospects. EMANATE Transcript & Slides
• Negative Sentiment: Multiple reports confirm Imcivree failed its late‑stage EMANATE weight‑loss trial for the targeted rare obesities, which directly increases near‑term clinical, regulatory and revenue uncertainty and was the primary driver of the share decline. Investors should watch for detailed efficacy/safety tables, any subgroup signals noted by management, and the company’s planned next steps. BioSpace: Imcivree Fails MSN: Trial Failure Coverage

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.